26 results on '"Aragri A."'
Search Results
2. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance
3. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
4. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
5. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
6. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
7. NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients
8. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection
9. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
10. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy
11. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
12. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
13. Natural HCV resistance is common in Italy and differently associated to genotypes
14. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
15. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
16. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
17. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment
18. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents
19. A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy
20. A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection
21. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors
22. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir + ribavirin: possible clinical implications in the liver transplant list management
23. Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release
24. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors
25. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?
26. P.33 DOES THE PRELOAD OF A NON-CALORIC CARBONATED BEVERAGE, DURING A STANDARDIZED SOLID AND LIQUID MEAL, AFFECT GASTRIC VOLUME AND ENERGY INTAKE IN HEALTHY SUBJECTS?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.